AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.040

-0.030-1.45%

Volume:2.02M

Turnover:4.13M

Market Cap:2.65B

PE:-31.90

High:2.090

Open:2.070

Low:2.020

Close:2.070

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:1.06

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.064

EPS(LYR):-0.064

ROE:-9.86%

ROA:-4.11%

PB:3.23

PE(LYR):-31.90

Loading ...

Overview Company News Filings

Mesoblast director Gregory George buys US$ 10.1 million common shares

Did FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?

Simply Wall St.

Mesoblast director Gregory George reports US$ 5.7 million common share purchase

Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO

Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy

Simply Wall St.

Mesoblast to webcast inaugural R&D Day outlining plan to double Ryoncil revenue

Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?

Simply Wall St.

Mesoblast wins FDA IND clearance for registrational Ryoncil trial in Duchenne muscular dystrophy

Mesoblast Receives Ind Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

THOMSON REUTERS

Mesoblast Ltd - FDA Clears Ryoncil Ind for Registration Trial in Dmd

THOMSON REUTERS

BRIEF-Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M

Mesoblast posts Ryoncil quarterly net sales of US$30.3 million

Ryoncil® Continues Successful First Year Launch With Net Sales of US$30.3M in March Quarter

THOMSON REUTERS

Mesoblast Ltd - Ryoncil Net Revenue for Quarter Increases to US$30.3M

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/MSB.AU/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.04,"timestamp":1790921520000,"preClose":2.07,"halted":0,"volume":2020698,"delay":0,"changeRate":-0.014492753623188312,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.06394930145470258,"marketStatus":"Market Closed","change":-0.03,"latestTime":"10-02 16:12:00 AEST","open":2.07,"high":2.09,"low":2.02,"amount":4125712,"amplitude":0.033816,"askPrice":2.06,"askSize":12300,"bidPrice":2.04,"bidSize":11868,"shortable":3,"etf":0,"ttmEps":-0.06394930145470258,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.07,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":1.0640542661143209,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.07,"auctionPrice":2.04,"auctionVolume":237933,"auction":3,"marketStatus":"盘后竞价","timestamp":1790921417508}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-4.11%","roe":"-9.86%","lyrEps":-0.063949,"volumeRatio":1.0640542661143209,"shares":1296862776,"dividePrice":0,"high":2.09,"amplitude":0.033816,"preClose":2.07,"low":2.02,"week52Low":1.88,"pbRate":"3.23","psRate":"15.28","week52High":3.31,"institutionHeld":0,"latestPrice":2.04,"committee":-0.017875,"eps":-0.06394930145470258,"divideRate":0,"volume":2020698,"delay":0,"ttmEps":-0.06394930145470258,"open":2.07,"prevYearClose":2.72,"prevWeekClose":2.16,"prevMonthClose":2.11,"prevQuarterClose":2.11,"fiveDayClose":2.16,"twentyDayClose":2.38,"sixtyDayClose":2.24,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627337437","title":"Mesoblast director Gregory George buys US$ 10.1 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2627337437","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627337437?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:20","pubTimestamp":1776079231,"startTime":"0","endTime":"0","summary":"Mesoblast director Gregory George reported purchases of ordinary shares, raising indirect beneficial ownership to 13,586,890 shares.Transactions were reported at prices ranging from A$ 1.41 to A$ 1.48 per share.Holdings were reported as held indirectly via James George or Grant George under power of attorney to George.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL1BFvcb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mesoblast director Gregory George buys US$ 10.1 million common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626889120","title":"Did FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626889120","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626889120?lang=en_us&edition=fundamental","pubTime":"2026-04-12 04:28","pubTimestamp":1775939339,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in 76 children with Duchenne muscular dystrophy, using time-to-stand at nine months as the primary approval endpoint.\nThis move extends the use of the first FDA-approved mesenchymal stromal cell therapy beyond steroid‑refractory pediatric graft-versus-host disease and leverages a partnership with Parent Project...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4585","BK7501","BK7067","MSB","BK7508","MSB.AU","LABU","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626146145","title":"Mesoblast director Gregory George reports US$ 5.7 million common share purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2626146145","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626146145?lang=en_us&edition=fundamental","pubTime":"2026-04-11 07:28","pubTimestamp":1775863711,"startTime":"0","endTime":"0","summary":"Mesoblast director Gregory George reported purchases of ordinary shares, lifting indirect beneficial ownership held through related parties.Holdings tied to James George rose to 13,586,890 ordinary shares.Holdings tied to Grant George increased to 8,324,072 ordinary shares.Purchase prices in filing ranged from A$ 1.42 to A$ 14.4 per ordinary share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL6hlBfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mesoblast director Gregory George reports US$ 5.7 million common share purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7508","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626130851","title":"Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2626130851","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626130851?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:01","pubTimestamp":1775764897,"startTime":"0","endTime":"0","summary":"Cardiff Oncology named board member Mani Mohindru as president and CEO, following her stint as interim CEO.Josh Muntner was appointed CFO effective April 6; he previously served as CFO of Imvax and Mesoblast.Ajay Aggarwal was named COO effective April 27; he most recently served as SVP and head of clinical development at Aclaris Therapeutics.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL6mHz76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014039.USD","BK7067","SG9999014005.SGD","BK4585","BK4588","BK4007","IE00BN0W2V16.EUR","CRDF","IE00B64PRP62.GBP","SG9999014013.SGD","NDAQ","SG9999014021.USD","LU2095319765.USD","IE00BN0W2W23.USD","MSB.AU","BK7501","ACRS","BK4139","BK4112","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626182261","title":"Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2626182261","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626182261?lang=en_us&edition=fundamental","pubTime":"2026-04-09 17:37","pubTimestamp":1775727454,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) is back in focus after the US Food and Drug Administration granted investigational new drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, a high-need pediatric indication.\nSee our latest analysis for Mesoblast.\nDespite the FDA news and Ryoncil sales updates, recent trading has been choppy, with a 90 day share price return decline of 33.88%, even as the 3 year total shareholder return stands at 119.59%. At A$2.03, recent moves suggest...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","BK4588","MESO","BK7508","BK4585","BK4139","BK7067","BK7501","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944553","title":"Mesoblast to webcast inaugural R&D Day outlining plan to double Ryoncil revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944553","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625944553?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:08","pubTimestamp":1775653695,"startTime":"0","endTime":"0","summary":"Mesoblast will host an R&D Day event on Wednesday, April 8, from 8:00 a.m. to 11:00 a.m. EST in New York City.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1xKR1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","BK4585","BK7508","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","BK7501","IE00B64PRP62.GBP","BK4588","SG9999014039.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625949485","title":"Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625949485","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625949485?lang=en_us&edition=fundamental","pubTime":"2026-04-08 16:35","pubTimestamp":1775637306,"startTime":"0","endTime":"0","summary":"Wondering if Mesoblast at around A$2.02 is giving you genuine value or just fresh volatility? This article walks through what the numbers are actually saying about the stock.\nThe share price has had a mixed run, with a 7 day return of an 11.0% decline and a 30 day return of a 4.3% decline, set against a year to date return of a 27.1% decline, a 1 year return of 25.9%, and a 3 year return of 112.0%.\nThese moves sit alongside ongoing attention on Mesoblast's position in the biotech sector and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-offering-value-after-recent-share-price","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-offering-value-after-recent-share-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","BK7067","MSB","MSB.AU","BK7501","BK7508","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625999488","title":"Mesoblast wins FDA IND clearance for registrational Ryoncil trial in Duchenne muscular dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2625999488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625999488?lang=en_us&edition=fundamental","pubTime":"2026-04-08 11:35","pubTimestamp":1775619345,"startTime":"0","endTime":"0","summary":"Mesoblast received FDA IND clearance on April 7, 2026 to move directly into a registrational trial of Ryoncil in Duchenne muscular dystrophy.Trial results have not been presented; efficacy and safety readouts are expected in the future from the planned study.Study will test whether Ryoncil can preserve muscle function and slow disease progression by targeting inflammation, without disclosing outcome metrics.Design calls for 76 patients aged 5 to 9 years, randomized to Ryoncil or placebo on top of standard of care.Mesoblast is working with Parent Project Muscular Dystrophy to support enrollment and trial awareness.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL8Spvxd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","NDAQ","BK7508","MSB.AU","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","BK7067","LU2095319765.USD","SG9999014039.USD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BK7501","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625999480","title":"Mesoblast Receives Ind Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2625999480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625999480?lang=en_us&edition=fundamental","pubTime":"2026-04-08 11:35","pubTimestamp":1775619319,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nTUA44G60J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625790995","title":"Mesoblast Ltd - FDA Clears Ryoncil Ind for Registration Trial in Dmd","url":"https://stock-news.laohu8.com/highlight/detail?id=2625790995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625790995?lang=en_us&edition=fundamental","pubTime":"2026-04-08 10:31","pubTimestamp":1775615482,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q12M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MESO","BK7067","MSB.AU","BK7501","BK4139","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625898634","title":"BRIEF-Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2625898634","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625898634?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:35","pubTimestamp":1775529307,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3MApril 7 (Reuters) - Mesoblast Ltd MSB.AX:RYONCIL NET REVENUE FOR QUARTER INCREASES TO US$30.3MFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MESO","BK4139","BK7508","MSB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625983826","title":"Mesoblast posts Ryoncil quarterly net sales of US$30.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2625983826","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625983826?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:04","pubTimestamp":1775523873,"startTime":"0","endTime":"0","summary":"Mesoblast posted Ryoncil net sales of US$30.3 million for quarter ended March 31, 2026.Revenue in first year of launch approached US$100 million.February and March sales growth offset January holiday seasonality.Ryoncil revenue supported balance sheet strength, label expansion plans, late-stage development programs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLvHm2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SG9999014013.SGD","BK7067","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","BK4585","IE00B64PRP62.GBP","BK7501","SG9999014005.SGD","LU2210149790.SGD","NDAQ","BK7508","BK4112","LU0314104364.USD","MSB.AU","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014021.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625983849","title":"Ryoncil® Continues Successful First Year Launch With Net Sales of US$30.3M in March Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2625983849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625983849?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:03","pubTimestamp":1775523838,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA3M92XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625998831","title":"Mesoblast Ltd - Ryoncil Net Revenue for Quarter Increases to US$30.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2625998831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625998831?lang=en_us&edition=fundamental","pubTime":"2026-04-07 08:13","pubTimestamp":1775520794,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7508","MESO","BK7501","MSB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":9,"totalSize":174,"code":"91000000","status":"200"}]}}